CAMCEVI leuprolide mesylate

Drug Class

Gonadotropin-releasing hormone (GnRH) receptor agonist

Mechanism

Provides continuous stimulation of GnRH receptors in the pituitary gland, leading to receptor downregulation and suppression of luteinizing hormone (LH) and testosterone.

Approved Indication

Advanced prostate cancer, per its FDA approval.

What This Means For Patients

Camcevi is a depot injection of a GnRH agonist used to lower testosterone levels in patients with advanced prostate cancer. Lowering testosterone helps slow the growth of hormone-dependent cancer cells, and it is accessible in the Boao Lecheng pilot zone.

Regulatory Approvals

• FDA — approved (2021) — source

Pivotal Clinical Evidence

• FP01C-13-001 — Shore et al., World J Urol 2020 (NCT02234037) — DOI

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-leuprolide-mesylate-advanced-prostate-cancer
• https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212166